-
Morgan Stanley Sees 70% Upside In GW Pharma
Tuesday, June 28, 2016 - 8:26am | 228Read More...GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) has announced positive top-line results from the first Phase 3 trial of Epidiolex in Lennox-Gastaut Syndrome [LGS]. Morgan Stanley’s Andrew Berens maintained an Overweight rating for the company, while raising the price target from $149 to $152....
-
Morgan Stanley Downgrades Relypsa, Expects Focus To Return To The Challenged Veltassa Launch & Cash Burn
Tuesday, June 7, 2016 - 8:39am | 248Read More...A review of the inspection document for ZS-9, launched by AstraZeneca plc (ADR) (NYSE: AZN), indicates that the FDA's concerns could be addressed within 4-6 months, resulting in rapid approval and competition for Veltassa’s launch by Relypsa Inc (NASDAQ: RLYP), Morgan Stanley’s...
-
Overhang For Relypsa Remains, Morgan Stanley Says
Friday, May 27, 2016 - 9:04am | 296Read More...A probable delay in the FDA approval of ZS-9, AstraZeneca plc’s (ADR) (NYSE: AZN) hyperkalaemia asset, could lend near-term upside to shares of Relypsa Inc (NASDAQ: RLYP). Morgan Stanley’s Andrew S Berens maintained an Equal-weight rating for the company, with a price target of $9....
-
Morgan Stanley's Berens Highlights Greater Payor Pushback For Relypsa's Veltassa
Friday, April 15, 2016 - 9:54am | 292Read More...Morgan Stanley’s AlphaWise survey revealed that awareness and current treatment patterns remained significant headwinds for Veltassa, the lead product of Relypsa Inc (NASDAQ: RLYP). Morgan Stanley’s Andrew S. Berens maintains an Underweight rating for the company, with a price target of...
-
Morgan Stanley Downgrades Intercept Shares To Underweight, Cuts Target To $80
Friday, April 8, 2016 - 9:01am | 358Read More...Although Ocaliva in primary biliary cholangitis (PBC) has received the backing of an FDA panel, the panel did not endorse the drug for use in patients with advanced PBC, while recommending restrictions for use in non-responders and cirrhotics due to concerns regarding liver toxicity and safety....
-
Morgan Stanley Upgrades Cempra To Overweight
Monday, November 16, 2015 - 8:58am | 314Read More...Cempra Inc (NASDAQ: CEMP) shares are down 26 percent in the last three months, and are trading significantly below their 52-week high of $46.99. Morgan Stanley’s Andrew S Berens upgraded the rating on the company from Equal-weight to Overweight, while raising the price target from $25...
-
Why These Two Firms Downgraded ZS Pharma Stock
Monday, November 9, 2015 - 9:38am | 525Read More...ZS Pharma Inc (NASDAQ: ZSPH) shares have gained 114 percent year-to-date, and are trading close to the high-end of their 52-week range of $34.35 - $89.40. Credit Suisse’s Vamil Divan and Morgan Stanley’s Andrew S Berens have downgraded their ratings on the company. The...
